SOURCE: BIOLASE Technology, Inc.

May 01, 2007 06:00 ET

BIOLASE Surpasses 2000 Unit Sales of Waterlase® MD

ezlase Demand Exceeds Company's Expectations

IRVINE, CA -- (MARKET WIRE) -- May 1, 2007 --BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that it has recently sold its 2000th Waterlase MD™ dental laser system since the system was launched in late 2004. The Company also noted that it has sold over 5600 Waterlase systems worldwide since inception, which includes both the Waterlase MD and its predecessor systems.

"We continue to believe that the Waterlase MD is the most advanced all-tissue laser system available in the dental market," commented President and CEO Jeffrey W. Jones. "We are very pleased to have reached this important milestone, and we look forward to an accelerating adoption rate in the future through our joint efforts with strategic partner Henry Schein."

Jones noted that BIOLASE is seeing growing traction in its recently launched ezlase™ soft tissue diode laser system. "I am also encouraged that demand for ezlase has exceeded our expectations," he added.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jeffrey W. Jones
    President & CEO

    Richard L. Harrison
    Executive Vice President and CFO of BIOLASE Technology, Inc.
    +1-949-361-1200

    or Jill Bertotti
    of Allen & Caron
    +1-949-474-4300